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INTRODUCTION
============

During the immediate period after solid organ transplantation, rejection of the transplanted organ as well as the short-term survival rate of the patient is of primary concern. Overcoming the shortcomings of currently available surgical techniques and immunosuppressants would allow for a longer life expectancy in more patients. Accordingly, greater emphasis has been placed on caring for chronic transplant-associated morbidities, which are the primary determinant of expectancy and quality of life in the long-term post-transplantation periods. The increased prevalence of macrovascular events in transplant recipients compared to non-transplant subjects remains a pivotal challenge to overcome. Among the established risk factors for the development of cardiovascular events in transplant recipients, attention and research has focused on abnormal glucose homeostasis in kidney transplant recipients. Therefore this review focuses on what is currently known about how genetics and pancreatic β-cell dysfunction related to the development of diabetes in kidney recipients.

INCIDENCE OF POSTRENAL TRANSPLANTATION DIABETES MELLITUS
========================================================

Hyperglycemia after renal transplantation leads to the development of microvascular morbidity as well as accelerated macrovascular events, resulting in reduced recipient survival \[[@B1]\]. In this regard, aggravation of pre-existing diabetes as well as new-onset transplant-associated hyperglycemia encompassing new onset diabetes mellitus (DM), impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) have been introduced as gluco-metabolic targets in an effort to reduce the risk of developing chronic transplant-associated morbidity and mortality by implementing proper management approaches during pre- and post-transplant stages \[[@B2]\]. Postrenal transplantation diabetes mellitus (PTDM), first described by Starzl et al. \[[@B3]\] in 1964, is defined as new-onset diabetes after solid organ transplantation. The definition of diabetes according to the American Diabetes Association (ADA) is a fasting plasma glucose \[FPG\] ≥7.0 mmol/L or a 2-hour post-load glucose ≥11.1 mmol/L, and this is routinely adopted when diagnosing PTDM. However, the incidence and prevalence of PTDM varies among studies depending on the criteria used to diagnose diabetes, the usage or kinds of immunosuppressants, characteristics of the subject population, and time after transplantation \[[@B4]\]. In the 1970s and early 1980s, steroids were considered the gold standard drug-of-choice and 40% to 60% of transplant recipients developed DM \[[@B5],[@B6]\]. Even with the advent of cyclosporine A (CsA) in 1978, the prevalence of PTDM ranges widely from 5% to 45% \[[@B7]-[@B12]\], which is 2 to 9 times more than that of DM in an age- and sex-matched general population. A meta-analysis involving 19 observational studies and controlled trials reported that the rates of PTDM in the first post-transplantation year range from 2% to 50%. Two of the largest epidemiologic studies investigating the incidence of PTDM in subjects on the waiting list for renal transplantation and transplant recipients \[[@B13],[@B14]\] demonstrated a 6% annual baseline incidence of new onset diabetes for the wait-listed subjects, and a 14% to 16% increase in the incidence of PTDM during the first post-transplantation year for transplant recipients. In the Korean population, it was previously reported that the overall incidence of PTDM was 39% at 1 year after transplantation and 35.1% at 7 years after transplantation \[[@B15]\]. Based on these results, PTDM might be especially accelerated in the first few post-transplantation months by the superimposition of transplant-related factors on baseline risks.

TRANSPLANT-ASSOCIATED RISK FACTORS AND TRADITIONAL TYPE 2 DIABETES RISK FACTORS OF PTDM
=======================================================================================

The risk factors associated with PTDM have been examined in many studies. Underlying baseline risk factors such as increased age, family history of diabetes, ethnicity, genetic variation, obesity, and hepatitis C are partially accountable for an increased underlying risk of PTDM in renal allograft recipients \[[@B16]-[@B18]\]. Non-modifiable risk factors of PTDM appear to be greater for patients who are older at the time of transplantation and have a familial history of diabetes \[[@B19]\]. Kidney transplant recipients older than 40 years of age are at greater risk of PTDM than younger recipients \[[@B11]\]. Gaining weight after transplantation, particularly among kidney transplant recipients, and infection with the hepatitis C virus \[[@B20]\] are modifiable risk factors for the development of PTDM. Similar to type 2 diabetes (T2D), weight gain after transplantation leads to insulin resistance \[[@B21]\] resulting in the development of PTDM.

In terms of transplant-related risk factors, usage and types of immunosuppressive agents are key to the aggravation or development of DM. PTDM is a major adverse effect of immunosuppressants. The diabetogenic effect of glucocorticoids, which has been well known since the early transplantation era, mainly results from both decreased peripheral glucose utilization and increased hepatic glucose production. The introduction of the 2nd generation of immunosuppressants of calcineurin inhibitors such as CsA and tacrolimus (Tac) into the field of transplantation has improved the outcome of organ transplants. However, their widespread therapeutic use is hindered by numerous reciprocal side effects shared between both drugs. Among them, new onset DM after transplantation, also known as PTDM, is of particular concern because of its frequent occurrence \[[@B22]\] and its associations with increased risk of cardiovascular diseases and lower survival rates.

Although the clinical features of T2D, such as insidious development, asymptomatic periods, etc., are similar to those of PTDM, some questions still remain regarding the incidence of PTDM among different ethnic groups. Interestingly, non-Caucasian kidney transplant recipients such as African-Americans, Hispanics, and Koreans are at greater risk of developing PTDM. These differences might be partially related to the pathophysiological development or aggravation of diabetes. The pathophysiologic nature of T2D is characterized by a progressive decline in pancreatic β-cell function and worsening insulin resistance, resulting in the failure of islets to respond to oral anti-diabetic drugs. However, the major determinant factors of PTDM remain controversial and there is some debate regarding whether the pathophysiology of PTDM is the result of decreased insulin secretion, increased insulin resistance, or both. For example, Ekstrand et al. \[[@B23]\] stated that insulin resistance and decreased insulin secretion may both be responsible, while Midtvedt et al. \[[@B24]\] suggested that insulin resistance may be the major contributor, and Shimizu et al. \[[@B25]\] reported that insulin resistance was improved after transplantation. Finally, in a well-designed 6-year prospective study, Hagen et al. \[[@B26]\] reported that impaired insulin secretion was the dominant mechanism for the development of PTDM. We have demonstrated that β-cell dysfunction was a major contributing factor to the development of PTDM in Korean subjects \[[@B15]\], which is consistent with Hagen et al.\'s results. As we previously described, hyperglycemia after transplantation might be accelerated by the superimposition of transplant-related factors on baseline risks. Considering the characteristics of Korean patients with T2D, whose secretory β-cell dysfunction was a major contributing factor to the development and aggravation of hyperglycemia \[[@B27],[@B28]\], different pharmacokinetic responses may augment the diabetogenic impact of immunosuppressants and superimpose upon conventional susceptible risks in the Korean population. In this regard, we also reported that the interaction between traditional genetic risk factors and transplant-associated risk factors such as calcineurin inhibitors plays an important role in the augmentation of established and new onset diabetes \[[@B29]\].

The association between PTDM and calcineurin inhibitor drugs is well-established. Previous *in vitro* studies on purified islets and insulin-producing β-cells have proposed several diabetogenic actions for CsA and Tac. Both drugs impair insulin secretion \[[@B30]-[@B33]\], decrease insulin content of the β-cell \[[@B34],[@B35]\] and impair insulin transcription \[[@B36],[@B37]\], although the primary mechanisms are not yet fully understood. In insulin-secreting cells, calcineurin is involved in the stimulation of insulin gene transcription through the activation of the transcription factor nuclear factor of activated T-cells (NFAT) \[[@B38]\]. Indeed, mice deficient in calcineurin B1 were shown to develop DM due to insufficient insulin production, while transgenic expression of constitutively active NFAT protected against DM \[[@B39]\]. In another study on immunosuppressants, rapamycin inhibited the mammalian target of rapamycin without affecting calcineurin activity, and also inhibited glucose-stimulated insulin secretion (GSIS) in β-cells \[[@B40],[@B41]\]. Although the therapeutic ranges of Tac and rapamycin are comparable, the potency of rapamycin in inhibiting insulin secretion seemed to be much lower than that of Tac in our study \[[@B29]\]. This may partly explain why rapamycin has less diabetogenic activity. However, the role of rapamycin in PTDM is still under investigation \[[@B17],[@B42]\]. Recently, the suppression of carbohydrate metabolism by rapamycin was suggested as a possible mechanism for the inhibition of insulin secretion \[[@B43]\]. However, the mechanism of action of rapamycin in the insulin secretory pathway is largely unknown.

PATHOPHYSIOLOGY OF PTDM: β-CELL DYSFUNCTION RATHER THAN INSULIN RESISTANCE
==========================================================================

Diabetes is caused by an imbalance in insulin production and peripheral insulin sensitivity. Despite some controversy, insulin secretory dysfunction is thought to be the dominant mechanism for the development of PTDM. We found that β-cell dysfunction plays a major role in the development of PTDM, which is consistent with previous reports \[[@B15],[@B21]\]. On the issue of \'Diabetes Care\' \[[@B15]\], we enrolled a total of 77 subjects with normal glucose tolerance (NGT), and an oral glucose tolerance test (OGTT) was performed 1 week before transplantation and repeated at 1 and 7 years after transplantation \[[@B15]\]. The overall incidence of PTDM was 39% at 1 year and 35.1% at 7 years post-transplantation.

The following conclusions were drawn based on the results of these studies: first, the fasting and 2-hour plasma glucose levels before transplantation in the IGT and PTDM after transplantation groups were significantly higher than those in the NGT after transplantation group. Second, patients with decreased insulin-secretory capacity, rather than decreased insulin sensitivity, were predisposed to developing PTDM. Compared with values before transplantation, the indices of insulin secretion and insulin sensitivity deteriorated at 1 year after transplantation. The insulin sensitivity index (ISI), representing insulin sensitivity, was not statistically different among groups after transplantation. However, the area under the curve of insulin on OGTT, representing insulin secretory function, was significantly lower in the PTDM group than in the NGT group. Proinsulin and proinsulin/insulin ratios have been proposed as indices for reduced maximum β-cell secretory capacity in patients with type 1 and type 2 diabetes \[[@B44],[@B45]\]. Maximum β-cell secretory capacity plays a pivotal role in the response to glucose loading, which is associated with deterioration in glucose tolerance. In our study, proinsulin/insulin ratios in the IGT and PTDM groups were significantly higher than in the NGT group at both pre- and post-transplantation periods. Taken together, this indicates that β-cell dysfunction was a more important factor for the development of PTDM.

GENETIC RISK FACTORS OF PTDM AND CLINICAL IMPLICATIONS OF ZINC TRANSPORTER-8 GENE IN RENAL TRANSPLANTATION
==========================================================================================================

PTDM may reflect a genetic predisposition to diabetes influenced by multiple environmental factors. Twenty-six percent of patients with a family history of diabetes develop PTDM, while only 14% of patients without a family history of diabetes develop PTDM \[[@B46]\]. This finding suggests that genetic variants typically associated with T2D are also likely associated with PTDM. However, only a few of the genetic polymorphisms associated with T2D have been studied in detail in transplant patients. Some studies have shown a significant association between PTDM and genetic polymorphisms. These polymorphisms were associated with genes involving insulin secretion (*KCNJ11*, *HNF4A*, *NFATc4*, *ENPP1/PC-1 \[K121Q\]*, *CCL5*, *VDR*) \[[@B47]-[@B52]\], insulin resistance (adiponectin, adiponectin receptor 1, *PAI-1*) \[[@B53]-[@B55]\], and oxidative stress (glutathione S-transferase gene, *SOD*) \[[@B56],[@B57]\]. One functional study and our three genetic association studies comprising a renal allograft cohort found that *TCF7L2*, a T2D susceptibility gene, led to a two-fold increase in the risk of T2D. In addition, we found that the *TCF7L2 rs7903146* genetic variation is also significantly associated with an increased risk of developing PTDM in kidney transplant recipients \[[@B58]\]. Zinc found in the zinc transporter-8 (ZnT-8) gene is involved in modulating insulin secretion. The R325W (rs13266634) non-synonymous polymorphism in the islet-specific zinc transporter protein gene *SLC30A8* is associated with T2D and also may be associated with a defect in insulin secretion. To investigate the association between genetic variations in the *SLC30A8* gene and PTDM in renal-transplant recipients \[[@B59]\], we recruited a total of 624 renal-allograft recipients without a documented history of diabetes. The prevalence of PTDM was 33.8% in patients with the R/R genotype, 26.8% in those with the R/W genotype, and 19.8% in those with the W/W genotype. In addition, a strong association between the number of W alleles and PTDM risk reduction (*P*=0.007) was found. Patients with at least one W allele had a lower risk of PTDM compared to those with the R/R genotype (R/W RR, 0.78, *P*=0.126; W/W RR, 0.52, *P*=0.007). The effect of the *SLC30A8* genotype remained significant even after adjusting for age, gender, body weight gain, and type of immunosuppressant (R/W hazard ratio \[HR\], 0.77, *P*=0.114; W/W HR, 0.58, *P*=0.026). Therefore the *SLC30A8 rs13266634* gene variation appears to be associated with protection against the development of PTDM in renal-allograft recipients.

There is an association between PTDM and 17 single nucleotide polymorphisms (SNPs) located within 15 genes. Genome-wide association studies determined that these genes were related to diabetes susceptibility \[[@B60]\]. We found an association between the development of PTDM and the following SNPs: *HHEX* (rs1111875, rs7923837, and rs5015480), *CDKAL1* rs10946398, *CDKN2A/B* rs10811661, *IGF2BP2* rs4402960, *FTO* rs8050136, *WFS1* rs734312, *JAZF1* rs864745, *CDC123/CAMK1D* rs12779790, *TSPAN8* rs7961581, *THADA* rs7578597, *ADAMTS9* rs4607103, *NOTCH2* rs1092391, and *KCNQ1* rs2237892. Six loci were significantly associated with PTDM development: *HHEX* rs1111875 (odds ratio \[OR\], 1.47; *P*=0.007), *HHEX* rs7923837 (OR, 2.32; *P*=0.014), *HHEX* rs5015480 (OR, 1.59; *P*=0.003), *CDKAL1* rs10946398 (OR, 1.43; *P*=0.008), *CDKN2A/B* rs10811661 (OR, 1.33; *P*=0.039), and *KCNQ1* rs2237892 (OR, 1.46; *P*=0.009).

Recently, we investigated the functional aspect of the zinc transporter gene, based on the hypothesis that the polymorphic residue at position 325 of ZnT-8 might determine susceptibility to CsA suppression of insulin secretion \[[@B29]\]. INS-1E cells expressing the W325 variant showed enhanced GSIS and were less sensitive to CsA suppression of GSIS. A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA and transported zinc ions into secretory vesicles more efficiently. Both Tac and rapamycin caused similar suppression of GSIS in cells expressing ZnT-8 R325. However, cells expressing ZnT-8 W325 were resistant to Tac, but not to rapamycin. Overexpression of the Down\'s syndrome candidate region-1 (DSCR1), an endogenous calcineurin inhibitor, and subsequent calcineurin inhibition significantly reduced GSIS in cells expressing the R325 but not the W325 variant, suggesting that differing susceptibility to CsA may be due to different interactions with calcineurin. These data suggest that the ZnT-8 W325 variant is protective against CsA-induced suppression of insulin secretion. Tolerance of ZnT-8 W325 to calcineurin activity may account for its protective effect in PTDM.

CONCLUSIONS
===========

DM is a serious and frequent complication of renal transplantation. Although DM ultimately results from decreased insulin secretion and increased insulin resistance, our data suggest that β-cell dysfunction, rather than insulin resistance, may be the main contributing factor in the development of PTDM. PTDM is not always permanent and may resolve within weeks or months, sometimes without treatment. The aforementioned risk factors seem to be related to the different courses of PTDM. The ability to predict a patient\'s risk for developing PTDM would be of considerable benefit in selecting appropriate immunosuppressive regimens for individuals.

Genotyping diabetes-related polymorphisms is one possible method for predicting a patient\'s risk for developing PTDM. Our data suggest that genetic variations such as *TCF7L2*, *SLC30A8*, *HHEX*, *CDKAL1*, *CDKN2A/B*, and *KCNQ1* are associated with PTDM in Korea. Notably, *SLC30A8* encodes for β-cell-specific ZnT-8. The same allelic variant (which is a substitution of tryptophan for arginine at residue 325) of ZnT-8 is also associated with reduced incidence of PTDM in renal allograft recipients ([Fig. 1](#F1){ref-type="fig"}). A single nucleotide substitution in *SLC30A8* confers resistance to CsA-induced β-cell dysfunction by altering susceptibility to calcineurin inhibition. Our data suggest that ZnT-8 might be an important molecule connecting calcineurin inhibition by CsA to downregulation of β-cell insulin secretion, and this signaling pathway might be a new therapeutic target for the treatment of CsA-induced β-cell complications that occur after organ transplantation.
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![Schematic representation of vesicular zinc transporter-8 (ZnT-8) expression and R325W polymorphism in pancreatic islet β-cells. The single-nucleotide polymorphism rs13266634 of *SLC30A8* is associated with postrenal transplantation diabetes mellitus (PTDM) in renal allograft recipients, as demonstrated by Kang et al. \[[@B59]\]. *SLC30A8* encodes ZnT-8, which is specifically expressed in β-cells. ZnT-8 promotes zinc accumulation in secretory vesicles, and vesicular zinc is important for the formation of the zinc-insulin hexamer. Calcineurin is the intracellular target of the immunosuppressive drugs CsA and tacrolimus, and calcineurin activity is known to play a role in insulin gene transcription through the regulation of NFATc activity (Reproduced from Kim I, et al. Pharmacogenomics J 2011;11:191-8, with permission from Nature Publishing Group, a division of Macmillan Publishers Limited) \[[@B29]\].](dmj-36-199-g001){#F1}
